Posttransplant gilteritinib maintenance therapy for pediatric acute myeloid leukemia with myelodysplasia-related changes with FLT3-internal tandem duplication
Corresponding Author
Kosuke Tamefusa
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Correspondence
Kosuke Tamefusa, Department of Pediatrics, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
Email: [email protected]
Search for more papers by this authorHisashi Ishida
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorKiichiro Kanamitsu
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Department of Pediatrics, National Hospital Organization Okayama Medical Center, Okayama, Japan
Search for more papers by this authorMotoharu Ochi
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorKaori Fujiwara
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorYasuhisa Tatebe
Department of Pharmacy, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorMichinori Aoe
Division of Medical Support, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorSeishiro Nodomi
Department of Pediatrics, Kurashiki Central Hospital, Okayama, Japan
Search for more papers by this authorKana Washio
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorCorresponding Author
Kosuke Tamefusa
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Correspondence
Kosuke Tamefusa, Department of Pediatrics, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
Email: [email protected]
Search for more papers by this authorHisashi Ishida
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorKiichiro Kanamitsu
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Department of Pediatrics, National Hospital Organization Okayama Medical Center, Okayama, Japan
Search for more papers by this authorMotoharu Ochi
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorKaori Fujiwara
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorYasuhisa Tatebe
Department of Pharmacy, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorMichinori Aoe
Division of Medical Support, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorSeishiro Nodomi
Department of Pediatrics, Kurashiki Central Hospital, Okayama, Japan
Search for more papers by this authorKana Washio
Department of Pediatrics, Okayama University Hospital, Okayama, Japan
Search for more papers by this authorThis case was previously published as meeting abstracts for the 63rd JSPHO abstract 2021 (Pediatr Blood Cancer. 2021;68(Suppl. 6):e29440).
REFERENCES
- 1Strahm B, Nöllke P, Zecca M, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia. 2011; 25: 455-462.
- 2Shimada A, Iijima-Yamashita Y, Tawa A, et al. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. Int J Hematol. 2018; 107: 586-595.
- 3Bolouri H, Farrar JE, Triche T, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018; 24: 103-112.
- 4Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33: 299-312.
- 5Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019; 381: 1728-1740.
- 6McCall D, Roth M, Mahadeo KM, et al. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv. 2021; 5: 5215-5219.
- 7Iwasaki Y, Nishiuchi R, Aoe M, et al. Positive minimal residual disease of FLT3-ITD before hematopoietic stem cell transplantation resulted in a poor prognosis of an acute myeloid leukemia. Acta Med Okayama. 2017; 71: 79-83.
- 8Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet Study. J Clin Oncol. 2009; 27: 5195-5201.
- 9Kinoshita A, Miyachi H, Matsushita H, et al. Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group. Br J Haematol. 2014; 167: 80-86.
- 10Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017; 377: 454-464.
- 11Burchert A. Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia. Haematologica. 2021; 106: 664-670.
- 12Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020; 38: 2993-3002.
- 13Bazarbachi A, Bug G, Baron F, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020; 105: 1507-1516.